Market Overview - The Shanghai Composite Index is at 3884.87 points, above the six-month moving average, with a slight increase of 0.03% [1] - The total trading volume of A-shares today is 21,403.55 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 47 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Haosheng Electronics (12.03%) - Senqilin (4.06%) - Shuguang Co., Ltd. (3.72%) [1] Stock Performance Data - The following stocks have notable performance metrics: - Haosheng Electronics: Today's increase of 14.32%, turnover rate of 7.33%, six-month average price of 21.38 yuan, latest price at 23.95 yuan [1] - Senqilin: Today's increase of 5.90%, turnover rate of 6.52%, six-month average price of 20.00 yuan, latest price at 20.81 yuan [1] - Shuguang Co., Ltd.: Today's increase of 5.15%, turnover rate of 10.89%, six-month average price of 3.74 yuan, latest price at 3.88 yuan [1]

Market Overview - The Shanghai Composite Index closed at 3888.00 points, above the six-month moving average, with a slight increase of 0.11% [1] - The total trading volume of A-shares reached 16993.57 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 46 A-shares have surpassed the six-month moving average today, with notable stocks including Shuguang Co., Zhengdan Co., and Dongbai Group, showing divergence rates of 4.78%, 4.68%, and 2.88% respectively [1] - Stocks with smaller divergence rates that have just crossed the six-month moving average include Jinjiang Hotels, Mingchen Health, and Spring Airlines [1] Top Stocks by Divergence Rate - The top three stocks with the highest divergence rates are: - Shuguang Co. (600303) with a price increase of 6.23%, turnover rate of 9.78%, six-month line at 3.74 yuan, latest price at 3.92 yuan, and a divergence rate of 4.78% [1] - Zhengdan Co. (300641) with a price increase of 6.11%, turnover rate of 6.57%, six-month line at 24.40 yuan, latest price at 25.54 yuan, and a divergence rate of 4.68% [1] - Dongbai Group (600693) with a price increase of 3.53%, turnover rate of 5.38%, six-month line at 6.27 yuan, latest price at 6.45 yuan, and a divergence rate of 2.88% [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Tianbang Food (002124) with a price increase of 3.30%, turnover rate of 4.80%, six-month line at 3.05 yuan, latest price at 3.13 yuan, and a divergence rate of 2.74% [1] - *ST Haiyuan (002529) with a price increase of 5.06%, turnover rate of 1.38%, six-month line at 6.68 yuan, latest price at 6.85 yuan, and a divergence rate of 2.53% [1] - Senqilin (002984) with a price increase of 4.22%, turnover rate of 4.06%, six-month line at 20.00 yuan, latest price at 20.48 yuan, and a divergence rate of 2.43% [1]

Company Overview - Sichuang Medical Technology Co., Ltd. is located in Hangzhou, Zhejiang Province, and was established on November 21, 2003. The company was listed on April 30, 2010. Its main business focuses on smart hospital solutions, including disease research management solutions, smart medical community solutions, healthcare service operations, and AI services based on big data [1][2]. Financial Performance - For the first half of 2025, Sichuang Medical achieved operating revenue of 545 million yuan, representing a year-on-year growth of 37.32%. However, the net profit attributable to the parent company was -51.83 million yuan, which is a year-on-year increase of 76.74% in losses [2]. - Since its A-share listing, the company has distributed a total of 532 million yuan in dividends, with no dividends distributed in the past three years [3]. Stock Performance - On August 26, the stock price of Sichuang Medical rose by 2.17%, reaching 3.77 yuan per share, with a trading volume of 84.04 million yuan and a turnover rate of 2.04%. The total market capitalization is 4.214 billion yuan [1]. - Year-to-date, the stock price has increased by 24.01%, with a 7.10% rise over the last five trading days, a 4.56% decline over the last 20 days, and a 2.17% increase over the last 60 days [1]. Shareholder Information - As of June 30, the number of shareholders of Sichuang Medical was 65,800, a decrease of 10.81% from the previous period. The average circulating shares per person increased by 12.11% to 16,914 shares [2]. Industry Classification - Sichuang Medical is classified under the Shenwan industry as part of the Computer-IT Services II-IT Services III sector. It is associated with concepts such as assisted reproduction, Healthy China, smart healthcare, family doctor concepts, and internet healthcare [2].

Core Viewpoint - The financial performance of Sichuang Medical (300078) shows significant revenue growth but also highlights challenges in profitability and cash flow management [1][3]. Financial Performance Summary - Total revenue for the first half of 2025 reached 545 million yuan, a year-on-year increase of 37.32% compared to 397 million yuan in 2024 [1]. - The net profit attributable to shareholders was -51.83 million yuan, improving by 76.74% from -22.3 million yuan in the previous year [1]. - The gross profit margin decreased to 8.57%, down 44.26% from 15.38% in the previous year [1]. - The net profit margin improved to -9.85%, a significant increase of 82.68% from -56.86% in 2024 [1]. - The total of selling, administrative, and financial expenses was 86.6 million yuan, accounting for 15.89% of revenue, a decrease of 49.01% year-on-year [1]. Cash Flow and Debt Management - Cash and cash equivalents increased by 151.92% due to increased borrowings [3]. - The company reported a significant reduction in interest-bearing debt, down 68.91% to 339 million yuan [1]. - Operating cash flow showed a decline of 28.0%, attributed to increased tax payments related to property disposals [3]. Operational Insights - Accounts receivable accounted for 50.24% of total revenue, indicating a large volume of outstanding payments [1]. - The company disposed of investment properties, which significantly impacted both revenue and costs, with a revenue contribution of 293.46 million yuan from property disposals [3]. - Research and development expenses decreased by 50.99%, reflecting a reduction in R&D personnel in the medical sector [3]. Historical Performance Context - The company's historical return on invested capital (ROIC) has been weak, with a median of 4% over the past decade and a particularly poor ROIC of -32.19% in 2024 [4]. - The company has experienced four years of losses since its listing, indicating challenges in maintaining profitability [4].

Core Viewpoint - 思创医惠 reported its 2025 semi-annual report, highlighting a significant presence of institutional investors holding 14.15% of its total shares as of August 22, 2025 [1] Institutional Investors - A total of 7 institutional investors disclosed their holdings in 思创医惠, with a combined shareholding of 158 million shares [1] - The institutional ownership increased by 0.02 percentage points compared to the previous quarter [1] Public Funds - One new public fund disclosed its holdings this period, namely 汇添富中证互联网医疗指数(LOF)A [1] Foreign Investment - One foreign fund, BARCLAYS BANK PLC, increased its holdings by 0.40% compared to the previous period [1] - A new foreign institution, J.P.Morgan Securities PLC-自有资金, disclosed its holdings this period [1] - The foreign institutions that did not disclose their holdings this period include 高盛国际-自有资金 and MERRILL LYNCH INTERNATIONAL [1]

Core Viewpoint - The company announced the approval of a proposal to utilize part of its idle self-owned funds for cash management, with a total limit of up to 800 million RMB [1] Group 1 - The sixth board meeting is scheduled for August 21, 2025, where the cash management proposal will be reviewed [1] - The company and its subsidiaries will invest in high-security, high-liquidity, and low-risk financial products [1] - The usage period for the funds is valid for 12 months from the date of shareholder meeting approval, allowing for rolling use within the limit [1]

证券代码：300078 证券简称：思创医惠 公告编号：2025-095 思创医惠科技股份有限公司 关于召开 2025 年第四次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 （一）股东会届次：2025 年第四次临时股东会 （二）股东会的召集人：公司董事会 （三）会议召开的合法、合规性：经公司第六届董事会第十次会议审议通过， 决定召开 2025 年第四次临时股东会，本次股东会的召集程序符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》的规定。 （四）会议召开的日期、时间： （1）现场会议召开时间：2025 年 9 月 8 日（星期一）14:45； （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025 年 9 月 8 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券 交易所互联网投票系统投票的具体时间为：2025 年 9 月 8 日 9:15-15:00 期间的 任意时间。 （五）会议召开方式：本次股东会采取现场表决与网络投票相结合的方式召 开。公司 ...

思创医惠科技股份有限公司 第六届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 证券代码：300078 证券简称：思创医惠 公告编号：2025-091 思创医惠科技股份有限公司（以下简称"公司"）第六届董事会第十次会议 于 2025 年 8 月 21 日在温州市苍南县灵溪镇春晖路 433-505 号公投大楼会议室以 现场表决和通讯表决相结合的方式召开。会议通知于 2025 年 8 月 11 日通过电子 邮件、电话方式送达各位董事。本次会议应出席董事 7 人，实际出席董事 7 人。 会议由董事长许益冉先生召集并主持，公司高级管理人员列席了会议。本次会议 的召集、召开和表决程序符合《中华人民共和国公司法》（以下简称"《公司法》"） 等法律法规和《公司章程》的规定。 二、董事会会议审议情况 1、审议通过了《关于<2025 年半年度报告>及其摘要的议案》 经与会董事审议，一致认为公司《2025 年半年度报告》全文及摘要包含的 信息公允、全面、真实地反映了本报告期的财务状况和经营成果等事项，所披露 的信息真实、准确、完整 ...

Group 1 - The company reported a revenue of 545 million yuan for the first half of 2025, representing a year-on-year growth of 37.32% [1] - The net profit attributable to shareholders of the listed company was -51.83 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -62.55 million yuan [1] - The basic earnings per share were -0.05 yuan [1]

第一章 总 则 第一条 为进一步完善思创医惠科技股份有限公司（以下简称"公司"）的 法人治理，规范独立董事专门会议的议事方式和决策程序，促进并保障独立董事 有效地履行职责，根据《中华人民共和国公司法》《上市公司独立董事管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等有关法律法规、规范性文件和《思创 医惠科技股份有限公司章程》（以下简称"《公司章程》"）的规定，制定本工作细 则。 第二条 独立董事专门会议是指全部由公司独立董事参加的会议。 独立董事是指不在公司担任除董事外的其他职务，并与其所受聘的公司及其 主要股东、实际控制人不存在直接或间接利害关系，或者其他可能影响其进行独 立客观判断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人等单位或 者个人的影响。 思创医惠科技股份有限公司 独立董事专门会议工作细则 （2025年8月修订） 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，独立董事应当按 照相关法律法规、中国证券监督管理委员会（以下简称"中国证监会"）规定、 深圳证券交易所业务规则、《公司章程》和本 ...